sotorasib and Cell-Transformation--Neoplastic

sotorasib has been researched along with Cell-Transformation--Neoplastic* in 1 studies

Reviews

1 review(s) available for sotorasib and Cell-Transformation--Neoplastic

ArticleYear
Therapeutics Targeting Mutant KRAS.
    Annual review of medicine, 2021, 01-27, Volume: 72

    Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of the downstream effectors of EGFR activation, regulating cellular switches and functions and triggering intracellular signaling cascades such as the MAPK and PI3K pathways. Of the three RAS isoforms expressed in human cells, all of which were linked to tumorigenesis more than three decades ago, KRAS is the most frequently mutated. In particular, point mutations in KRAS codon 12 are present in up to 80% of KRAS-mutant malignancies. Unfortunately, there are no approved KRAS-targeted agents, despite decades of research and development. Recently, a revolutionary strategy to use covalent allosteric inhibitors that target a shallow pocket on the KRAS surface has provided new impetus for renewed drug development efforts, specifically against KRAS

    Topics: Acetonitriles; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA, Neoplasm; Humans; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines

2021